tiprankstipranks
Trending News
More News >
Oneview Healthcare PLC Chess Depository Interests repr 1 (AU:ONE)
:ONE

Oneview Healthcare Chess Depository Interests repr 1 (ONE) AI Stock Analysis

Compare
8 Followers

Top Page

AU

Oneview Healthcare Chess Depository Interests repr 1

(OTC:ONE)

Rating:45Neutral
Price Target:
AU$0.50
▲(78.57%Upside)
Oneview Healthcare's overall stock score reflects significant challenges in financial performance due to ongoing losses and negative cash flows. The technical analysis is neutral, providing little support to counterbalance the weak financials. Valuation metrics are unfavorable, as evidenced by a negative P/E ratio.

Oneview Healthcare Chess Depository Interests repr 1 (ONE) vs. iShares MSCI Australia ETF (EWA)

Oneview Healthcare Chess Depository Interests repr 1 Business Overview & Revenue Model

Company DescriptionOneview Healthcare is a company operating within the healthcare technology sector, focusing on delivering patient engagement solutions. The company provides a platform that integrates various healthcare systems to enhance patient and caregiver experiences. Their core products include interactive patient engagement systems that facilitate communication, education, and entertainment for patients during their hospital stay.
How the Company Makes MoneyOneview Healthcare generates revenue primarily through the sale and licensing of its patient engagement platform to hospitals and healthcare facilities. The company employs a subscription-based model for its software solutions, which provides a steady stream of recurring revenue. Additionally, Oneview benefits from implementation fees for initial system setup and ongoing support and maintenance services. Strategic partnerships with healthcare providers and technology companies also contribute to its earnings by expanding its market reach and enhancing its product offerings.

Oneview Healthcare Chess Depository Interests repr 1 Financial Statement Overview

Summary
Oneview Healthcare's financial performance is hindered by persistent net losses and negative cash flows. Despite modest revenue growth and slight improvements in gross profit margin, the overall financial health remains weak due to ongoing profitability challenges and reliance on external financing.
Income Statement
35
Negative
The company has struggled with profitability, evident from consistent negative EBIT and net income figures over recent years. Revenue has shown modest growth, with a 5.3% increase from 2023 to 2024, but margins remain under pressure. The Gross Profit Margin improved slightly, indicating some operational efficiency, yet the persistent net losses hinder overall performance.
Balance Sheet
40
Negative
The balance sheet shows a moderate debt-to-equity ratio, reflecting relatively low leverage. However, the company's equity ratio has been fluctuating, indicating instability in asset financing. Although stockholders' equity has grown, it remains susceptible to ongoing net losses. The overall equity position is improving but remains fragile.
Cash Flow
30
Negative
Cash flow from operations is consistently negative, which, combined with capital expenditures, results in negative free cash flow. There is a reliance on financing activities to support cash flow, which could pose risks if external funding becomes less available. The ratio of operating cash flow to net income indicates that cash generation efficiency is low.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
9.89M9.40M8.92M9.73M7.10M
Gross Profit
6.67M6.16M5.35M5.31M4.72M
EBIT
-11.36M-8.37M-10.76M-8.01M-8.23M
EBITDA
-11.26M-7.88M-15.38M-7.42M-8.18M
Net Income Common Stockholders
-10.84M-8.93M-10.87M-8.19M-9.45M
Balance SheetCash, Cash Equivalents and Short-Term Investments
13.83M11.55M6.41M15.18M6.80M
Total Assets
25.96M21.92M12.75M21.09M14.25M
Total Debt
1.15M935.32K543.01K1.20M1.51M
Net Debt
-12.68M-10.61M-5.87M-13.97M-5.29M
Total Liabilities
12.71M12.78M10.50M11.19M10.18M
Stockholders Equity
13.25M9.14M2.26M9.90M4.07M
Cash FlowFree Cash Flow
-10.52M-7.79M-10.24M-4.09M-7.94M
Operating Cash Flow
-10.47M-7.26M-10.20M-4.03M-7.69M
Investing Cash Flow
-459.78K-521.38K-44.52K-65.26K-249.35K
Financing Cash Flow
13.14M13.04M-100.11K12.22M4.95M

Oneview Healthcare Chess Depository Interests repr 1 Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.28
Price Trends
50DMA
0.27
Positive
100DMA
0.29
Negative
200DMA
0.31
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
54.98
Neutral
STOCH
94.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ONE, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.27, and below the 200-day MA of 0.31, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 54.98 is Neutral, neither overbought nor oversold. The STOCH value of 94.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ONE.

Oneview Healthcare Chess Depository Interests repr 1 Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AUCGS
76
Outperform
$210.97M21.8517.87%18.30%35.70%
AUBMT
57
Neutral
AU$92.86M-11.80%14.56%13.36%
AUPCK
55
Neutral
AU$66.31M-457.46%21.93%10.34%
AUALC
54
Neutral
AU$123.55M-5.63%-11.96%7.50%
54
Neutral
$5.41B3.27-45.10%3.29%16.81%0.02%
AUM7T
49
Neutral
$81.42M-9.88%24.29%6.49%
AUONE
45
Neutral
AU$212.21M
5.87%4.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.28
-0.03
-11.11%
AU:CGS
Cogstate Ltd
1.47
0.35
30.67%
AU:M7T
Mach7 Technologies
0.34
-0.33
-49.24%
AU:BMT
Beamtree Holdings Ltd
0.31
0.09
40.91%
AU:ALC
Alcidion Group Limited
0.10
0.06
150.00%
AU:PCK
PainChek Ltd
0.04
0.01
33.33%

Oneview Healthcare Chess Depository Interests repr 1 Corporate Events

Oneview Healthcare PLC Announces Quotation of New Securities
May 16, 2025

Oneview Healthcare PLC announced the quotation of 1,232,788 CHESS Depositary Interests on the Australian Securities Exchange, marking a significant step in its strategic financial operations. This move is expected to enhance the company’s market presence and provide greater flexibility in its capital management, potentially benefiting stakeholders and reinforcing its position in the healthcare technology sector.

The most recent analyst rating on (AU:ONE) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Oneview Healthcare Chess Depository Interests repr 1 stock, see the AU:ONE Stock Forecast page.

Oneview Healthcare Reports Strong Q1 2025 with Strategic Expansions and Innovations
Apr 23, 2025

Oneview Healthcare PLC reported a net cash outflow of €1.6 million for Q1 2025, with strong customer receipts inflows of €4.2 million, reflecting improved financial performance compared to the previous year. The company is actively expanding its market presence through strategic partnerships and product innovations, including the launch of its AI-driven Virtual Patient Assistant, Ovie. The company is also progressing with significant deployment projects and is in contract negotiations with major healthcare systems, positioning itself for continued growth despite potential tariff impacts.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.